Gilead still hasn’t made up its mind about Arcus’ drugs, but there’s a top exec at the biotech it definitely wants

Gilead made clear it’s in for the long I/O game when it outlined a $2 billion deal with Arcus — including $375 million paid upfront — that would span a full decade. One year in, it’s tapping a trusty steward to manage that alliance.